Jing Medicine Technology will collaborate with ShanghaiTech University in a $100M partnership to discover and develop novel small molecule cancer drugs.
February 6, 2018 -- Jing Medicine Technology (Shanghai) will collaborate with ShanghaiTech University in a $100 million partnership to discover and develop novel small molecule cancer drugs. Jing Medicine will own global development and commercialization rights to the candidates, while ShanghaiTech University will receive upfront and milestone payments plus royalties. Initially, the partnership will focus on novel IP-protected compounds from a Ligand-directed Protein Degradation Platform, developed by Professor Biao Jiang.
